Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 16, 2016, Pages 4470-4475

  Peterson, Teresa E ^a,b,e   Kirkpatrick, Nathaniel D ^a,f   Huang, Yuhui ^a,g   Farrar, Christian T ^a   Marijt, Koen A ^a,h   Kloepper, Jonas ^a   Datta, Meenal ^a,c   Amoozgar, Zohreh ^a   Seano, Giorgio ^a   Jung, Keehoon ^a   Kamoun, Walid S ^a,i   Vardam, Trupti ^a,j   Snuderl, Matija ^a,k   Goveia, Jermaine ^a,l   Chatterjee, Sampurna ^a   Batista, Ana ^a,m   Muzikansky, Alona ^a   Leow, Ching Ching ^d   Xu, Lei ^a   Batchelor, Tracy T ^b   Duda, Dan G ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Tufts University   (United States)

^d MEDIMMUNE   (United States)

^e Wilson Sonsini Goodrich and Rosati   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g SOOCHOW UNIVERSITY   (China)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MERRIMACK PHARMACEUTICALS   (United States)

^j MAYO GRADUATE SCHOOL   (United States)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m Trends in Molecular Medicine   (United States)

more..

Author keywords

Anti angiogenic therapy; Colony stimulating factor 1; Macrophage; Tumor immunity; Tumor microenvironment

Indexed keywords

ANGIOPOIETIN 2; CEDIRANIB; COLONY STIMULATING FACTOR 1; MEDI 3617; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANG2 PROTEIN, MOUSE; CANCER ANTIBODY; PANCREATIC RIBONUCLEASE; QUINAZOLINE DERIVATIVE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL; CANCER GROWTH; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EDEMA; GLIOBLASTOMA; HEMISPHERE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MACROPHAGE ACTIVATION; MEDIAN SURVIVAL TIME; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; MACROPHAGE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOBLASTOMA; MACROPHAGES; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RIBONUCLEASE, PANCREATIC;

EID: 84964409623     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525349113     Document Type: Article

References (71)

1. Lu-Emerson C, et al. (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33(10):1197-1213.
2. Friedman HS, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740.
3. Kreisl TN, et al. (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745.
4. Vredenburgh JJ, et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259.
5. Vredenburgh JJ, et al. (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729.
6. Chinot OL, et al. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709-722.
7. Gilbert MR, et al. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699-708.
8. Wick W, et al. (2015) LB-05 phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: The EORTC 26101 trial. Neuro-oncol 17(Suppl 5):v1.
9. Batchelor TT, et al. (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212-3218.
10. Winkler F, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553-563.
11. Kamoun WS, et al. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27(15):2542-2552.
12. Batchelor TT, et al. (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817-2823.
13. Batchelor TT, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95.
14. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
15. Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26(5):605-622.
16. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of 6angiogenesis. Nature 473(7347):298-307.
17. Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18(38):5356-5362.
18. Hu B, et al. (2003) Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci USA 100(15):8904-8909.
19. Lee OH, et al. (2006) Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5):419-428.
20. Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153(5):1459-1466.
21. Zagzag D, et al. (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159(2):391-400.
22. Hu B, Cheng SY (2009) Angiopoietin-2: Development of inhibitors for cancer therapy. Curr Oncol Rep 11(2):111-116.
23. Daly C, et al. (2006) Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 103(42):15491-15496.
24. Kim I, et al. (2000) Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19(39):4549-4552.
25. Teichert-Kuliszewska K, et al. (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49(3):659-670.
26. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10(3):165-177.
27. Chae SS, et al. (2010) Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16(14):3618-3627.
28. di Tomaso E, et al. (2011) Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. Cancer Res 71(1):19-28.
29. Sie M, et al. (2009) The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg 110(1):147-155.
30. Huang Y, et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109(43):17561-17566.
31. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39-51.
32. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22(2):231-237.
33. Pyonteck SM, et al. (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19(10):1264-1272.
34. Leow CC, et al. (2012) MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40(5):1321-1330.
35. Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW (2015) Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer 3:52.
36. Hashizume H, et al. (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70(6):2213-2223.
37. Koh YJ, et al. (2010) Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18(2):171-184.
38. Brown JL, et al. (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9(1):145-156.
39. Daly C, et al. (2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73(1):108-118.
40. Kienast Y, et al. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19(24):6730-6740.
41. Keskin D, et al. (2015) Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Reports 10(7):1066-1081.
42. Huang H, et al. (2011) Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17(5):1001-1011.
43. Oliner J, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507-516.
44. Falcón BL, et al. (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175(5):2159-2170.
45. Holopainen T, et al. (2012) Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104(6):461-475.
46. Mazzieri R, et al. (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19(4):512-526.
47. Sorensen AG, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402-407.
48. Gerstner ER, Batchelor TT (2012) Antiangiogenic therapy for glioblastoma. Cancer J 18(1):45-50.
49. Emblem KE, et al. (2013) Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19(9):1178-1183.
50. Batchelor TT, et al. (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059-19064.
51. Kwilas AR, Donahue RN, Tsang KY, Hodge JW (2015) Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron 2(1):e677.
52. Mantovani A, Allavena P (2015) The interaction of anticancer therapies with tumorassociated macrophages. J Exp Med 212(4):435-445.
53. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065-1073.
54. De Palma M, Naldini L (2006) Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766(1):159-166.
55. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE (2000) Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 192(2):150-158.
56. Lin EY, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66(23):11238-11246.
57. Hanahan D, Coussens LM (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309-322.
58. DeNardo DG, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1):54-67.
59. Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 antiinflammatory macrophage phenotype in growth of human gliomas. J Pathol 216(1):15-24.
60. Noy R, Pollard JW (2014) Tumor-associated macrophages: From mechanisms to therapy. Immunity 41(1):49-61.
61. Kloepper J, et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 113:4476-4481.
62. Yasuda S, et al. (2013) Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2(VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 172(3):500-506.
63. Hamzah J, et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453(7193):410-414.
64. Meisen WH, et al. (2015) The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res 21(14):3274-3285.
65. Stockmann C, et al. (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456(7223):814-818.
66. Beatty GL, et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612-1616.
67. De Palma M, et al. (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4):299-311.
68. Lu-Emerson C, et al. (2013) Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-oncol 15(8):1079-1087.
69. Vakoc BJ, et al. (2009) Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15(10):1219-1223.
70. Yuan F, et al. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54(17):4564-4568.
71. Xu L, Xie K, Fidler IJ (1998) Therapy of human ovarian cancer by transfection with the murine interferon beta gene: Role of macrophage-inducible nitric oxide synthase. Hum Gene Ther 9(18):2699-2708.